Profound Medical restates Q1-Q3 2024 financials due to $472k revenue error; Q4 revenue up 108% YoY

Profound Medical Corp.

Revenue overstated by $472k in Q1 2024; prior 6-K filings for Q1-Q3 2024 no longer reliable.
Q4 2024 revenue $4.2M (+108% YoY); net loss $4.9M ($0.20/share) vs $8.9M ($0.42) in Q4 2023.
Full year 2024 revenue $10.7M; net loss $27.8M ($1.12/share) vs $28.3M ($1.34) in 2023.
New $10M CIBC revolving credit line matures March 2027; option to increase to $15M if trailing revenue exceeds $15M.
Mathieu Burtnyk promoted to President; Tom Tamberrino appointed CCO; CAPTAIN trial enrollment complete.

item 1.01 item 2.02 item 2.03 item 4.02 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.